These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

212 related articles for article (PubMed ID: 9123707)

  • 1. Combined hormono/chemotherapy as primary treatment for metastatic prostate cancer: a randomized, multicenter study of orchiectomy alone versus orchiectomy plus estramustine phosphate. The Dutch Estracyt Study Group.
    Janknegt RA; Boon TA; van de Beek C; Grob P
    Urology; 1997 Mar; 49(3):411-20. PubMed ID: 9123707
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Experience in advanced prostatic cancer: orchiectomy and flutamide versus orchiectomy and estramustine phosphate.
    Roessler W; Hinke A; Wieland WF
    Urology; 1994 Feb; 43(2 Suppl):57-60. PubMed ID: 8116134
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Estramustine phosphate combined with orchidectomy as first-line therapy in patients with prostate carcinoma. Effect of age on survival.
    Pelger RC; Lycklama A Nijeholt Ga; Zwinderman AH; Hamdy NA
    Cancer; 2002 May; 94(10):2596-601. PubMed ID: 12173326
    [TBL] [Abstract][Full Text] [Related]  

  • 4. [Clinicopathological evaluation of etoposide or estramustine phosphate in castrated patients with advanced prostatic cancer].
    Matsuda H; Nonomura K; Nagamori S; Shinohara N; Koyanagi T; Maru A; Matsuno T; Fujieda J; Minami S; Morita H
    Nihon Hinyokika Gakkai Zasshi; 1995 Oct; 86(10):1530-7. PubMed ID: 7474602
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Combination of docetaxel, estramustine phosphate, and zoledronic acid in androgen-independent metastatic prostate cancer: efficacy, safety, and clinical benefit assessment.
    Efstathiou E; Bozas G; Kostakopoulos A; Kastritis E; Deliveliotis C; Antoniou N; Skarlos D; Papadimitriou C; Dimopoulos MA; Bamias A
    Urology; 2005 Jan; 65(1):126-30. PubMed ID: 15667877
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Immediate estrogen or estramustine phosphate therapy versus deferred endocrine treatment in nonmetastatic prostate cancer: a randomized multicenter study with 15 years of followup. The South Sweden Prostate Cancer Study Group.
    Lundgren R; Nordle O; Josefsson K
    J Urol; 1995 May; 153(5):1580-6. PubMed ID: 7714978
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Estramustine phosphate versus placebo as second line treatment after orchiectomy in patients with metastatic prostate cancer: DAPROCA study 9002. Danish Prostatic Cancer Group.
    Iversen P; Rasmussen F; Asmussen C; Christensen IJ; Eickhoff J; Klarskov P; Larsen E; Mogensen P; Mommsen S; Rosenkilde P
    J Urol; 1997 Mar; 157(3):929-34. PubMed ID: 9072602
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Orchiectomy and orchiectomy plus mitomycin C for metastatic prostate cancer in patients with poor prognosis: the final results of a European Organization for Research in Cancer Therapy Genitourinary Group Trial.
    de Reijke TM; Keuppens FI; Whelan P; Kliment J; Robinson MR; Rea LA; Sylvester RJ
    J Urol; 1999 Nov; 162(5):1658-64; discussion 1664-5. PubMed ID: 10524892
    [TBL] [Abstract][Full Text] [Related]  

  • 9. A randomized phase II trial of personalized peptide vaccine plus low dose estramustine phosphate (EMP) versus standard dose EMP in patients with castration resistant prostate cancer.
    Noguchi M; Kakuma T; Uemura H; Nasu Y; Kumon H; Hirao Y; Moriya F; Suekane S; Matsuoka K; Komatsu N; Shichijo S; Yamada A; Itoh K
    Cancer Immunol Immunother; 2010 Jul; 59(7):1001-9. PubMed ID: 20146063
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Estramustine phosphate (estracyt) following androgens in men with refractory stage D2 prostate cancer.
    Boccardo F; Decensi A; Guarneri D; Martorana G; Giberti C; Giuliani L
    Cancer Chemother Pharmacol; 1988; 22(2):172-4. PubMed ID: 3409448
    [TBL] [Abstract][Full Text] [Related]  

  • 11. The present role of estramustine phosphate in advanced prostate cancer.
    Van Poppel H; Baert L
    Prog Clin Biol Res; 1991; 370():323-41. PubMed ID: 1924466
    [TBL] [Abstract][Full Text] [Related]  

  • 12. The flare in alkaline phosphatase activity post-orchidectomy predicts which patient may benefit from early chemotherapy in metastatic prostate cancer.
    Pelger RC; Lycklama A Nijeholt GA; Zwinderman AH; Hamdy NA
    Prostate; 2002 Feb; 50(2):119-24. PubMed ID: 11816020
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Docetaxel with or without estramustine for estramustine refractory castration-resistant prostate cancer: a single institution experience.
    Nakano K; Ohta S; Komatsu K; Kubo T; Nukui A; Suzuki K; Kurokawa S; Kobayashi M; Morita T
    BMC Urol; 2012 Feb; 12():3. PubMed ID: 22353627
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Early versus deferred androgen suppression in the treatment of advanced prostatic cancer.
    Nair B; Wilt T; MacDonald R; Rutks I
    Cochrane Database Syst Rev; 2002; (1):CD003506. PubMed ID: 11869665
    [TBL] [Abstract][Full Text] [Related]  

  • 15. A comparison of the effect of diethylstilbestrol with low dose estramustine phosphate in the treatment of advanced prostatic cancer: final analysis of a phase III trial of the European Organization for Research on Treatment of Cancer.
    Smith PH; Suciu S; Robinson MR; Richards B; Bastable JR; Glashan RW; Bouffioux C; Lardennois B; Williams RE; de Pauw M
    J Urol; 1986 Sep; 136(3):619-23. PubMed ID: 3525866
    [TBL] [Abstract][Full Text] [Related]  

  • 16. The importance of prognostic factors in the interpretation of two EORTC metastatic prostate cancer trials. European Organization for Research and Treatment of Cancer (EORTC) Genito-Urinary Tract Cancer Cooperative Group.
    Sylvester RJ; Denis L; de Voogt H
    Eur Urol; 1998; 33(2):134-43. PubMed ID: 9519354
    [TBL] [Abstract][Full Text] [Related]  

  • 17. [Complete androgen blockade (orchiectomy + flutamide) versus androgen blockade with cytostasis (orchiectomy + estramustine) in the treatment of virginal advanced prostate cancer].
    Flamm J; Fischer M
    Wien Klin Wochenschr; 1988 Sep; 100(17):589-92. PubMed ID: 3055689
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Estramustine phosphate compared with diethylstilbestrol. A randomized, double-blind, crossover trial for stage D prostate cancer.
    Benson RC; Gill GM
    Am J Clin Oncol; 1986 Aug; 9(4):341-51. PubMed ID: 3529921
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Combination of LHRH analog with somatostatin analog and dexamethasone versus chemotherapy in hormone-refractory prostate cancer: a randomized phase II study.
    Dimopoulos MA; Kiamouris C; Gika D; Deliveliotis C; Giannopoulos A; Zervas A; Alamanis C; Constantinidis C; Koutsilieris M
    Urology; 2004 Jan; 63(1):120-5. PubMed ID: 14751362
    [TBL] [Abstract][Full Text] [Related]  

  • 20. [Clinical efficacy of leuprolide acetate and combined treatment with estramustine for advanced prostate cancer].
    Saito S; Nakashima J; Nakajima Y; Ikeuchi K; Shibayama T; Nagakura K; Naide Y; Hayakawa M; Ogawa Y; Hata M; Nakazono M; Hasegawa S; Oda T; Kimura S; Nakamura S; Matsunaga J; Fujioka T; Tanoguchi H; Aoki S; Yamamoto Y; Izawa A; Kimura S; Suzuki K; Tazaki H; Murai M;
    Nihon Hinyokika Gakkai Zasshi; 2001 Nov; 92(7):682-93. PubMed ID: 11766367
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 11.